Platelet-derived serotonin links vascular disease and tissue fibrosis. - Test2 - elhamkhani - TriplyDB

Platelet-derived serotonin links vascular disease and tissue fibrosis.

Platelet-derived serotonin links vascular disease and tissue fibrosis.

http://www.wikidata.org/entity/Q34973681

about

Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis Microvessel mechanobiology in pulmonary arterial hypertension: cause and effect Diabetic Microvascular Disease and Pulmonary Fibrosis: The Contribution of Platelets and Systemic Inflammation Animal models of systemic sclerosis: their utility and limitations.Molecular targets for therapy in systemic sclerosis One-pot synthesis of magnetic nanoclusters enabling atherosclerosis-targeted magnetic resonance imaging Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis.Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study Role of MicroRNAs in Fibrosis.Old medications and new targeted therapies in systemic sclerosis.Inhibition of angiogenesis by platelets in systemic sclerosis patients.Platelets in lung biology.Gut-derived serotonin is a multifunctional determinant to fasting adaptation.A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo.The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis.Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.The pathogenesis, diagnosis and treatment of Raynaud phenomenon.The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis.The complex regulation of TGF-β in cardiovascular disease.Serotonin paracrine signaling in tissue fibrosis Is there evidence for vasculitis in systemic sclerosis?Regulation of wound healing and organ fibrosis by toll-like receptors.Targeted therapies for systemic sclerosis.Platelets and autoimmunity.A platelet-inspired paradigm for nanomedicine targeted to multiple diseases.Secrets of platelet exocytosis - what do we really know about platelet secretion mechanisms?New renal drug development to face chronic renal disease.Current frontiers in systemic sclerosis pathogenesis.Fibrogenesis, novel lessons from animal models.Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.Pathogenic role of platelets in rheumatoid arthritis and systemic autoimmune diseases. Perspectives and therapeutic aspects.Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.Human xylosyltransferases--mediators of arthrofibrosis? New pathomechanistic insights into arthrofibrotic remodeling after knee replacement therapy.5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis.Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model.Mean platelet volume seems to be a valuable marker in patients with systemic sclerosis.

P2860

Q24633568-EDD9160D-9D5F-4E72-91F4-F1022273EC33 Q26749091-585A826B-8031-4F9F-90C1-A51645F439AA Q27009717-91F2901C-A8C8-4505-A869-73A9C037B575 Q28073977-B6D4AE3A-8D4B-41AE-B315-B0508895FAA0 Q28390528-75579703-DED9-48A7-AE8E-790C8B0B4F33 Q28484123-FA0BD832-BB69-4724-82C6-F179DDFD2AAD Q30829383-F2B9B5D6-879E-4A04-9620-6E9CC106C8EE Q34721223-CD9E3E83-D113-45B7-8D14-69CA58AE9AFA Q35863725-C01C8A88-9837-470C-B461-22046DFF95AD Q36020320-7DE60865-710F-440C-9779-440A7CDF1DB2 Q36093326-09498CEB-DAB3-4527-9820-E1A38FE1F29C Q36154430-31246065-9A6C-4C72-BF08-5E0C40179A6E Q36301680-B174326B-5601-48F4-B417-39C70625108D Q36897267-65E61702-ED82-4850-BFFD-1279509FCF31 Q36966737-41558BEB-04A2-4DD5-9BAA-6C54BA51F015 Q37031192-36F43D19-4859-40A1-8B25-D0727732A4EE Q37176705-F4ECD30B-6F13-4DA9-B275-A5771069633C Q37413166-BF9623D8-F585-46EF-A0AB-45512C284BC1 Q37634132-D1DB90C2-5BF6-44D8-825A-1A37099B00AB Q37638268-D2D0BE80-365C-41FD-966F-9DCCAADB44D6 Q38025285-D293E774-3C3B-477C-A768-EA7FFC63DE7D Q38042445-EFE9C21A-B5A8-4F25-8736-9D16329BBA31 Q38048775-FCA9FA98-CCBF-4D04-8BC1-E6BBAF9AA786 Q38049023-2016F43D-7ED7-4F2F-AA7B-AEB7BF248D4E Q38052089-79EC4C2E-6828-4E22-8C26-11A7B8A68BB7 Q38065649-CCF8EEAD-EE91-4C87-8B29-E72CE136E079 Q38097276-43C95A5C-E663-4023-A9DB-256BFF43E742 Q38101678-13217809-C4E8-4C29-93A3-462CC58A0B4B Q38145567-83DAC848-6E7F-4BED-B75E-659ED82C3FB7 Q38192676-D9C5CC05-0968-4F9B-8822-8FCC3ADC3697 Q38246640-5EF245F0-3E6E-44DE-B774-2914A8766270 Q38364957-652CA9DD-8D67-4697-85C4-BE32AD7ADE06 Q38542592-C8265C1C-AEC9-44ED-8DBA-F84E1FB97DC0 Q38636049-50B492F8-F90E-4D60-81A8-7D56691A794C Q38799905-D26B9BE2-6247-48FB-B5D1-F9D036A06F2A Q38956376-DF9F43E7-8038-4D40-ACC2-85E6886AD407 Q38980276-35D87A6D-8CA7-4130-AD2A-D5A20B03C9ED Q39202142-E497EB4A-26F5-40F7-9698-8EA1F2C5DF2B Q39461570-C2A6ABFA-2584-456D-A212-0CE17A7EADEA Q40134411-15D783EC-B6D0-4062-8044-C15FF5B7C207

P2860

Platelet-derived serotonin links vascular disease and tissue fibrosis.

http://www.wikidata.org/entity/Q34973681

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@ast

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@en

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@nl

type

label

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@ast

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@en

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@nl

prefLabel

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@ast

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@en

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@nl

P1433

Q34973681-4EADC236-EBC9-421B-BD45-C3ED3AE3EB42

P1476

Q34973681-C147A9B5-F07C-4E8B-B4A6-03A6A1429E71

P2093

Q34973681-2EA89C60-7BDF-430D-8061-7BA5E9B8498F

Q34973681-578C8E81-41E7-4946-8CA4-1A339BBD1959

Q34973681-5BC19DE4-419E-4909-B3F5-195F8653D736

Q34973681-5DA4B5E9-D5B9-4BC1-BE70-5F33255225D7

Q34973681-69429DFC-ECDC-4E55-BE4B-D66463ADD543

Q34973681-783262C7-B422-41E5-A595-270E7D313EE8

Q34973681-85F0DE34-8F05-48C6-8A02-18141AE42044

Q34973681-93D8AB41-3CDB-465C-89E9-D721F34F7F99

Q34973681-B14FFBBC-F99C-4753-AE87-84ACC0E49886

Q34973681-CB303AF8-661E-4F6E-9C5F-B0755B91E521

P2860

Q34973681-0873DCF3-237D-49C3-B2A1-D40733F8F868

Q34973681-11A9B2E4-E206-49B7-A947-7267513675C8

Q34973681-1CC6470B-2569-4549-8A5C-C43B35949DFD

Q34973681-2179176E-0D78-4594-BFC4-1EF14B38B719

Q34973681-23906BF0-56F4-41A1-8335-D1508032E234

Q34973681-25F1D786-62CF-4676-B982-F52250B06670

Q34973681-27B3BF8D-0421-4345-B952-34DA9BD4FC1C

Q34973681-2EB639E7-2728-4C67-9F63-870EC1AC255B

Q34973681-33816E8A-AC0F-4D53-8705-F3472750B321

Q34973681-41DC74BA-765C-44FF-AF1C-FBA66C5EAAB0

P304

Q34973681-C2524EAB-10E1-4335-AC81-CD7314393BDC

P31

Q34973681-A3F264E0-C8B9-46CD-A607-8DD6DF2BA114

P356

Q34973681-21877A12-C3F0-4B17-BD48-76797D2AEF3C

P407

Q34973681-306FC33D-093D-4DBA-8B72-589D12C24954

P433

Q34973681-B73D5F3F-81B8-4CCE-A945-E9B98D5F84F5

P478

Q34973681-18A7065B-0EC9-4EFA-8B81-58C798204ABF

P50

Q34973681-4CDD0177-FCA1-4785-A033-529A0BDBBEF5

Q34973681-6B99B3DB-E3C3-4C08-A35E-89E7C4F10E87

Q34973681-BAEE709D-2657-4113-930E-D3CEC9A261AA

Q34973681-F08F3772-E056-4EF9-88C6-6A8C926011C1

P577

Q34973681-BAE61D1B-3E42-470C-BC83-A4CE67C10A24

P5875

Q34973681-9750A561-724C-48FC-96BF-F0531DC645A8

P698

Q34973681-FB49A811-5180-4AB2-A991-57E60FF1311A

P921

Q34973681-1ea21b88-793a-4118-bb50-c301297c5398

P932

Q34973681-4D657792-DA6B-4251-BF34-EEF32660B522

P356

P1433

Journal of Experimental Medicine

P1476

Platelet-derived serotonin links vascular disease and tissue fibrosis.

@en

P2093

Alfiya Akhmetshina

http://www.w3.org/2001/XMLSchema#string

Angelika Horn

http://www.w3.org/2001/XMLSchema#string

Astrid Jüngel

http://www.w3.org/2001/XMLSchema#string

Clara Dees

http://www.w3.org/2001/XMLSchema#string

Jochen Zwerina

http://www.w3.org/2001/XMLSchema#string

Jörg H W Distler

http://www.w3.org/2001/XMLSchema#string

Katrin Palumbo

http://www.w3.org/2001/XMLSchema#string

Natalia Alenina

http://www.w3.org/2001/XMLSchema#string

Nicole Reich

http://www.w3.org/2001/XMLSchema#string

Oliver Distler

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors

Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors

Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

Functional activity of serotoninergic and melatoninergic systems expressed in the skin

A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome

Drugs and valvular heart disease

Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis

Synthesis of serotonin by a second tryptophan hydroxylase isoform

P304

961-972

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20101629

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

208

http://www.w3.org/2001/XMLSchema#string

P50

Christian Beyer

Gerhard Krönke

P577

2011-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51075756

http://www.w3.org/2001/XMLSchema#string

P698

21518801

http://www.w3.org/2001/XMLSchema#string

P921

P932

3092343

http://www.w3.org/2001/XMLSchema#string